Pfizer's novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of Phase 2/3 EPIC-HR study

Pfizer
Business & Industry News Channel
Pfizer
GlaxoSmithKline
Roche
Pfizer
Novartis
Petrovax Pharm
Roche